2. Academic Validation
  3. Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo

Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo

  • Cell. 2025 Sep 4;188(18):4896-4912.e19. doi: 10.1016/j.cell.2025.06.023.
James P Cooney 1,  Ashley Hirons 2,  Natasha Jansz 3,  Cody C Allison 1,  Peter Hickey 4,  Charis E Teh 1,  Tania Tan 1,  Laura F Dagley 5,  Jumana Yousef 5,  David Yurick 6,  Georges Khoury 2,  Simon P Preston 1,  Philip Arandjelovic 1,  Kathryn C Davidson 1,  Lewis J Williams 1,  Stefanie M Bader 1,  Le Wang 7,  Reet Bhandari 1,  Liana Mackiewicz 7,  Merle Dayton 7,  William Clow 7,  Geoffrey J Faulkner 8,  Daniel H Gray 1,  Lloyd Einsiedel 9,  Damian F J Purcell 2,  Marcel Doerflinger 1,  Marc Pellegrini 10
Affiliations

Affiliations

  • 1 Division of Infectious Diseases and Immune Defence, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.
  • 2 Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • 3 Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, VIC, Australia; Mater Research Institute-University of Queensland, TRI Building, Woolloongabba, QLD 4102, Australia.
  • 4 Division of Infectious Diseases and Immune Defence, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia; Advanced Technology & Biology, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • 5 Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia; Advanced Technology & Biology, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • 6 Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, VIC, Australia; UCB Pharma, Smyrna, GA, USA.
  • 7 Division of Infectious Diseases and Immune Defence, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • 8 Mater Research Institute-University of Queensland, TRI Building, Woolloongabba, QLD 4102, Australia; Queensland Brain Institute, University of Queensland, Brisbane, QLD 4072, Australia.
  • 9 Department of Medicine, Alice Springs Hospital, Alice Springs, NT, Australia.
  • 10 Division of Infectious Diseases and Immune Defence, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia; Centenary Institute Medical Research Foundation, Camperdown, Sydney, NSW 2050, Australia. Electronic address: m.pellegrini@centenary.org.au.
PMID: 40645177 DOI: 10.1016/j.cell.2025.06.023
Abstract

This study investigated preventative and therapeutic agents against human T cell lymphotropic virus type-1 subtype-C (HTLV-1c) Infection. We established and characterized a humanized mouse model of HTLV-1c Infection and identified that HTLV-1c disease appears slightly more aggressive than the prevalent HTLV-1 subtype-A (HTLV-1a), which may underpin increased risk for infection-associated pulmonary complications in HTLV-1c. Combination antiretroviral therapy with tenofovir and dolutegravir at clinically relevant doses significantly reduced HTLV-1c transmission and disease progression in vivo. Single-cell RNA Sequencing (scRNA-seq) and intracellular flow cytometry identified that HTLV-1c Infection leads to dysregulated intrinsic Apoptosis in infected cells in vivo. Pharmacological inhibition using BH3 mimetic compounds against Mcl-1, but not Bcl-2, Bcl-xL, or Bcl-W, killed HTLV-1c-infected cells in vitro and in vivo and significantly delayed disease progression when combined with tenofovir and dolutegravir in mice. Our data suggest that combination antiretroviral therapy with Mcl-1 antagonism may represent an effective, clinically relevant, and potentially curative strategy against HTLV-1c.

Keywords

BH3 mimetics; HTLV-1 ATLL; HTLV-1a; HTLV-1c; antiretrovirals; combination therapy; humanized mice; scRNA-seq.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z